Clinical trial
A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis.
To investigate the efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active Ulcerative Colitis (UC).
| Category | Value |
|---|---|
| Study start date | 2011-11-07 |